KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.

Eiji Kikuchi, Michiel S Van der Heijden, Begoña P Valderrama, Shilpa Gupta, Jens Bedke, Sang Joon Shin, Jian-Ri Li, Jun Guo, Pongwut Danchaivijitr, Ravindran Kanesvaran, Se Hoon Park, Wen-Pin Su, Shuya Kandori, Woo Kyun Bae, Alvin Wong, Seema Gorla, Abhishek Bavle, Xuesong Yu, Yi-Tsung Lu, Thomas Powles

Int J Clin Oncol 31(3) 436-446

PMID41563650
PMCIDPMC12932347
DOI10.1007/s10147-025-02950-8
发表日期2026-01-21
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: In the phase 3 EV-302 study, enfortumab vedotin-pembrolizumab (EV + P) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with untreated locally advanced/metastatic urothelial carcinoma (la/mUC). We present a post hoc analysis in a pan-Asian population. METHODS: Patients from China, Japan, Singapore, South Korea, Taiwan, and Thailand received 3-week cycles of EV (1.25 mg/kg; intravenously; Days 1 and 8) plus P (200 mg; intravenously; Day 1) or chemotherapy (gemcitabine [Days 1 and 8] plus cisplatin/carboplatin [Day 1]). Primary endpoints were PFS and OS. Secondary endpoints included objective response rate (ORR) and safety. RESULTS: Overall, 176 patients were included (EV + P, n = 94; chemotherapy, n = 82). Median follow-up was 28.9 months for EV + P recipients and 26.6 months for chemotherapy recipients. EV + P prolonged PFS and OS versus chemotherapy, reducing the risk of disease progression or death by 63% (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.24-0.57) and death by 67% (HR, 0.33; [95% CI, 0.20-0.54]), respectively. Confirmed ORR was 72.2% versus 35.0%. Grade ≥ 3 treatment-related adverse events occurred in 66.0% of EV + P recipients and 68.4% of chemotherapy recipients. Most commonly maculopapular rash (11.7%) and hyperglycemia (10.6%) for EV + P and neutropenia (25.0%), anemia (19.7%), and neutrophil count decreased (18.4%) for chemotherapy. CONCLUSION: EV + P demonstrated a clinically meaningful survival benefit in Asian patients with untreated la/mUC, with no new safety signals observed, consistent with the global EV-302 study. Results support guideline recommendations for EV + P as preferred first-line therapy in la/mUC. CLINICAL TRIAL REGISTRATION: NCT04223856 (registered January 8, 2020).

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2 Kaplan–Meier plot for the pan-Asian population for progression-free survival by BICR A and overall survival B . BICR blinded independent central review; CI confidence interval; HR hazard ratio; NE not estimable; NR not reached; OS overall survival; PFS progression-free survival

A

progression-free survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
B

overall survival

Fig. 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient disposition: CONSORT. Data cutoff date was August 8, 2024. a Six patients in the chemotherapy group did not receive treatment due to withdrawal of consent. CONSORT Consolidated Standards of Reporting Trials
非 KM Figure